Skip to main content
. 2023 May 3;3(3):327–333. doi: 10.21873/cdp.10219

Table III. Multivariate analyses for overall survival of patients treated with immune checkpoint inhibitors.

graphic file with name cdp-3-331-i0001.jpg

irAEs: Immune-related adverse events; NLR: neutrophil lymphocyte ratio; RCC; renal cell carcinoma. Statistically significant p-values are shown in bold.